Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | CCND1 | P24385 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CCND2 | P30279 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11977218 | 0.89 | CDK4 (0.55) | CDK4CCND1CCNE1CDK2CCND2 | |
| SCHEMBL4191359 | 0.88 | CDK4 (0.59) | SYKALKCDK4CCND1CCNE1 | |
| SCHEMBL7706847 | 0.81 | ALK (0.58) | SYKALKCDK4CCND1CCNE1 | |
| SCHEMBL4189207 | 0.81 | ALK (0.57) | SYKALKCDK4CCND1CCNE1 | |
| SCHEMBL4195845 | 0.80 | CDK4 (0.56) | SYKALKCDK4CCND1CCNE1 | |
| SCHEMBL11976965 | 0.76 | CDK4 (0.53) | SYKALKCDK4CCND1CCNE1 | |
| SCHEMBL20418753 | 0.76 | CDK4 (0.49) | ALKCDK4CCND1CCND2CCND3 | |
| SCHEMBL4186969 | 0.76 | ALK (0.56) | SYKALKCDK4CCND1CCNE1 | |
| SCHEMBL11977036 | 0.76 | CDK4 (0.54) | SYKALKCDK4CCND1CCNE1 | |
| SCHEMBL7714506 | 0.76 | CCND3 (0.55) | CDK4CCND1CCNE1CDK2CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | SYK 1001/4885ALK 794/4885CDK4 4/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | SYK 1001/4885ALK 794/4885CDK4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.